SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics disclosed that the German Federal Cartel Office…

Esperion Therapeutics, Inc. · 8-K filed Jun 9, 2026 at 16:01 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 9, 2026 at 16:01 ET

Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition by an affiliate of ArchiMed SAS, effective June 2, 2026. The merger remains subject to other conditions, including HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026.

  • Bundeskartellamt cleared the merger effective June 2, 2026.
  • Special stockholder meeting to vote on the merger is set for July 8, 2026.
  • Completion still requires HSR waiting period expiration/termination and stockholder adoption of the merger agreement.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access